Patents by Inventor David D. Deininger

David D. Deininger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD)
    Publication number: 20230159502
    Abstract: Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).
    Type: Application
    Filed: April 2, 2021
    Publication date: May 25, 2023
    Inventors: Simon GIROUX, Michael Philip CLARK, Michael Aaron BRODNEY, Philippe Marcel NUHANT, Emily Elizabeth ALLEN, Robert Francis FIMOGNARI, Jr., Mariam ZAKY, Michael John BOYD, David D. DEININGER, Hu ZHANG, Hongbo DENG, Philip Noel COLLIER, Brad MAXWELL, Nathan D. WAAL, Steven M. RONKIN, Jian WANG, Qing TANG, Gabrielle Simone FLEMING, Peter JONES, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL, Upul Keerthi BANDARAGE
  • ISOTOPICALLY ENRICHED AZAINDOLES
    Publication number: 20160168147
    Abstract: The present invention relates to deuterated compounds that are useful for inhibiting Janus kinases and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: February 22, 2016
    Publication date: June 16, 2016
    Inventors: Christopher Lee Brummel, Francois Maltais, David D. Deininger, Brian Ledford, Warren Dorsch
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20140031277
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: May 24, 2013
    Publication date: January 30, 2014
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kevin M. Cottrell, John J. Court, David D. Deininger, Luc J. Farmer, Janos Pitlik, Robert B. Perni
  • Gyrase inhibitors and uses thereof
    Patent number: 8404852
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: March 26, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • GYRASE INHIBITORS AND USES THEREOF
    Publication number: 20130023525
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Application
    Filed: April 24, 2012
    Publication date: January 24, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE
    Publication number: 20130012430
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: June 27, 2012
    Publication date: January 10, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 8314141
    Abstract: The present invention relates to Formula (II) compounds having the structure as well as to their use in methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: November 20, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • c-MET protein kinase inhibitors
    Patent number: 8232406
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 31, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • C-MET PROTEIN KINASE INHIBITORS
    Publication number: 20110059936
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 10, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, JR., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • c-MET protein kinase inhibitors
    Patent number: 7872031
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: January 18, 2011
    Assignee: Vertex Pharmaceuticals incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20100330109
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: December 16, 2009
    Publication date: December 30, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kevin M. Cottrell, John J. Court, David D. Deininger, Luc J. Farmer, Janos Pitlik, Robert B. Perni
  • INHIBITORS OF C-MET AND USES THEREOF
    Publication number: 20100190774
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Application
    Filed: April 8, 2010
    Publication date: July 29, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: David J. Lauffer, Alexander Aronov, Pan Li, David D. Deininger, Kira McGinty, Dean Stamos, Jon H. Come, Michelle Stewart
  • Inhibitors of c-Met and uses thereof
    Patent number: 7728017
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: June 1, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Alexander Aronov, Pan Li, David D. Deininger, Kira McGinty, Dean Stamos, Jon H. Come, Michelle Stewart
  • Gyrase inhibitors and uses thereof
    Patent number: 7727992
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: June 1, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Joseph Drumm, Anne-Laure Grillot, Yusheng Liao, Patricia Oliver-Shaffer, Dean Stamos
  • GYRASE INHIBITORS AND USES THEREOF
    Publication number: 20100105701
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Application
    Filed: June 11, 2003
    Publication date: April 29, 2010
    Inventors: Paul S. Charifson, David D. Deininger, Joseph Drumm, Anne-Laure Grillot, Yusheng Liao, Patricia Oliver-Shaffer, Dean Stamos
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7683033
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: March 23, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John J. Court, David D. Deininger, Luc J. Farmer, Janos Pitlik, Robert B. Permi
  • Gyrase inhibitors and uses thereof
    Patent number: 7582641
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Grant
    Filed: November 11, 2004
    Date of Patent: September 1, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • Gyrase inhibitors and uses thereof
    Patent number: 7569591
    Abstract: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: August 4, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud LeTiran, Joseph Drumm
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE
    Publication number: 20090143312
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: February 14, 2008
    Publication date: June 4, 2009
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Gyrase inhibitors and uses thereof
    Patent number: 7495014
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: February 24, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiensheng Wang, Arnaud LeTiran, Joseph Drumm